X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the agreement, Daewoong Pharmaceutical will have the exclusive right to market, sell and distribute Primocyn (hypochlorous acid) Skin Solution products, containing Sonoma's Microcyn technology, in South Korea.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Dermatology Product Name: Primocyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daewoong Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 31, 2023
Details:
Regenacyn Plus (Hypochlorous acid), is an anti-allergic, anti-inflammatory and antipruritic most effective scar gel. It has dual action healing process for infection control, improving new and old keloid and hypertrophic scars and accelerating wound healing.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Dermatology Product Name: Regenacyn Plus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Reliefacyn (hypochlorous acid) is antipruritic, anti-inflammatory, and anti-allergic. Reliefacyn alleviates symptoms such as red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling, and effectively manages symptoms of eczema/atopic dermatitis.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Dermatology Product Name: Reliefacyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
SpectrumX has confirmed scientific advice meeting with MHRA and will discuss the available data supporting the commencement of human trials with SPX-001 (Hypochlorous Acid) protocol for Phase Ib human volunteer study, prior to submission of CTA submission.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 03, 2022
Details:
Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Dermatology Product Name: Regenacyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Sonoma has agreed on a 10-year license, distribution and supply agreement with its distribution partner Brill International S.L. to market the eye care product under the private label Ocudox™ in the European markets of Italy, Germany, Spain, Portugal and the United Kingdom.
Lead Product(s): Hypochlorous Acid
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Brill International S.L
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
